[go: up one dir, main page]

WO2013028527A1 - Compositions et procédés pour traiter le cancer - Google Patents

Compositions et procédés pour traiter le cancer Download PDF

Info

Publication number
WO2013028527A1
WO2013028527A1 PCT/US2012/051369 US2012051369W WO2013028527A1 WO 2013028527 A1 WO2013028527 A1 WO 2013028527A1 US 2012051369 W US2012051369 W US 2012051369W WO 2013028527 A1 WO2013028527 A1 WO 2013028527A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
amino acid
modified
clathrin
heavy chain
Prior art date
Application number
PCT/US2012/051369
Other languages
English (en)
Inventor
Joel A. YBE
Sarah N. FONTAINE
Original Assignee
Indiana University Research And Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research And Technology Corporation filed Critical Indiana University Research And Technology Corporation
Publication of WO2013028527A1 publication Critical patent/WO2013028527A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Clathrin is normally involved in receptor-mediated endocytosis (RME), but its function can be redirected to promote cancer suppressor p53-mediated transactivation. To do this, trimeric clathrin must be made monomeric, but how this occurs is not understood.
  • the characteristic shape of clathrin ( Figure 1 ) enables this three-legged molecule to self-assemble into polyhedral coats in receptor- mediated endocytosis (RME). Although the formation of clathrin lattices is energetically favored and spontaneous, RME requires a host of accessory proteins.
  • Adaptor proteins [1 , 2, 3], non-visual arrestins [4, 5], and Hsc70 [6, 7, 8, 9] associate with the N-terminal ⁇ -propeller domain of clathrin heavy chain (CHC) [10, 1 1 ].
  • This propeller domain is joined to a filamentous portion (aa543-1576) that is subdivided into the distal and proximal domains with a flexible knee joint between them [12, 13] and ends in the trimerization domain [14, 15].
  • the proximal domain in each leg binds two types of clathrin light chain subunits (LCa and LCb [16, 17, 18]) in mammals and one light chain in yeast clathrin [19].
  • HIPs Huntingtin-lnteracting Proteins
  • a modified clathrin heavy chain polypeptide, or an active fragment thereof comprising an amino acid replacement of cysteine with an amino acid other than cysteine in an unmodified clathrin heavy chain polypeptide at a locus corresponding to amino acid cysteine-1573 of a clathrin heavy chain polypeptide comprising an amino acid sequence set forth in SEQ ID NO:1 .
  • a modified clathrin heavy chain polypeptide comprising the amino acid sequence of Formula (1 ):
  • Xi is an amino acid residue selected from the group consisting of Ala, Val, Leu, lie, Met, Gin, Glu, Gly, His, Met, Ser, Thr, Trp, and Tyr;
  • (1 -1572) is a peptide chain including the first 1572 amino acid residues of the human CHC polypeptide counted from the N-terminal end or an analog thereof or derivative thereof.
  • (1574-1675) is a peptide chain including amino acid residues 1574 to 1675 of the human CHC polypeptide, or an analog thereof or a derivative thereof.
  • Figure 1 illustrates the clathrin trimerization domain structure without light chains.
  • Figure 2 illustrates the identification of a topological switch in clathrin.
  • Figure 3 illustrates nuclear localization of clathrin hub following specific mutations in helix 7j.
  • the articles “a,” “an,” “the,” and “said” are intended to mean that there are one or more of the elements.
  • the terms “comprising,” “containing,” “including,” and “having” are intended to be inclusive and mean that there may be additional elements other than the listed elements.
  • the term “or” means any one member of a particular list and also includes any combination of members of that list, unless otherwise specified.
  • a "clathrin heavy chain” polypeptide refers to any CHC polypeptide (protein) including, but not limited to, recombinantly-produced polypeptide, synthetically-produced polypeptide and CHC extracted from cells.
  • Clathrin heavy chain polypeptides include precursor clathrin heavy chain polypeptide having signal sequences and mature clathrin heavy chain polypeptides.
  • CHC polypeptides include related polypeptides from different species including, but not limited to animals of human and nonhuman origin.
  • CHC polypeptide amino acid sequences can contain varying number of amino acid residues. For example, the human CHC of SEQ ID NO: 1 polypeptide has 1675 amino acids.
  • polypeptides also can be shorter than 1675 amino acids, provided that a polypeptide retains an activity of the clathrin heavy chain.
  • the clathrin triskelion is composed of three clathrin heavy chains and three light chains interacting at their C-termini.
  • the three heavy chains provide the structural backbone of the clathrin lattice, and the three light chains are thought to regulate the formation and disassembly of a clathrin lattice.
  • Human CHC's include allelic variant isoforms among individuals, alternative splice variants, synthetic molecules from nucleic acids, protein isolated from human tissue and cells, and modified forms thereof.
  • CHC polypeptides exhibit allelic variation and species variation. Included, in various aspects, are fragments of CHC that are of sufficient length to be functionally active; such fragments are known and/or can be identified by assays to determine the promotion of p53-mediated transactivation.
  • CHC polypeptides have been isolated from a variety of species. Exemplary CHC polypeptides of non- human origin include, but are not limited to, bovine, murine, amphibian, insect, and avian CHC polypeptides, and include, but are not limited to CHC, allelic variant isoforms, synthetic molecules produced from encoding nucleic acid molecules, protein isolated from non-human tissue and cells, and modified forms thereof.
  • Non- human CHC also includes fragments of CHC that are of sufficient length to be functionally active.
  • an "activity" or "property” of a CHC polypeptide (protein) refers to any activity or property exhibited by a CHC protein that can be assessed. Such activities include those observed or exhibited in vitro or in vivo (typically referred to as a biological activity). These activities include, but are not limited to, nuclear localization and the promotion of p53-mediated transactivation.
  • fragment of CHC polypeptide refers to any fragment that exhibits one or more biological activities of the full-length polypeptide.
  • polypeptide oligopeptide
  • peptide and “protein” are used interchangeably herein to refer to polymers of amino acids of any length.
  • the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids.
  • the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component.
  • polypeptides containing one or more analogs of an amino acid including, for example, non-naturally occurring amino acids
  • unmodified clathrin refers to a starting polypeptide (protein) that is selected for modification.
  • the starting unmodified target polypeptide can be the naturally occurring, wild type (WT) form of a protein.
  • WT wild type
  • the starting unmodified polypeptides previously can have been altered or mutated, such that they differ from the native wild-type isoform, but are nonetheless referred to herein as starting unmodified polypeptides relative to the subsequently modified polypeptides disclosed herein.
  • polypeptides known in the art that have previously been modified to have a desired increase or decrease in a particular activity compared to an unmodified reference protein can be selected and used herein as the starting "unmodified protein.”
  • a polypeptide that has been modified from its native form by one or more single amino acid changes and possesses either an increase or decrease in a desired activity, such as anti-cancer therapeutic activity can be utilized with the methods provided herein as the starting unmodified polypeptide for further modification of either the same or a different activity.
  • polypeptides known in the art that previously have been modified to have a desired alteration, such as an increase or decrease, in a particular activity compared to an unmodified or reference protein can be selected and used as provided herein for identification of structurally homologous loci on other structurally homologous polypeptides.
  • a polypeptide that has been modified by one or more single amino acid changes and possesses either an increase or decrease in a desired activity e.g., localization in the nucleus
  • a desired activity e.g., localization in the nucleus
  • modified polypeptide refers to derivatives of a protein which may be obtained, for example, by subjecting an unmodified protein, for example wild-type CHC, to one or more modifications.
  • Example modifications include mutations, truncations, enzymatic digestions, and/or changing its post-translational modifications. Mutations may be one or more amino acid replacements, insertions, deletions and/ or any combination thereof.
  • a position or positions corresponding to an amino acid position of a protein refers to amino acid positions that are determined to correspond to one another based on sequence and/or structural alignments with a specified reference protein.
  • a position corresponding to an amino acid position of human CHC set forth as SEQ ID NO: 1 can be determined empirically by aligning the sequence of amino acids set forth in SEQ ID NO: 1 with a particular polypeptide of interest.
  • Corresponding positions can be determined by such alignment by one of skill in the art using manual alignments or by using the numerous alignment programs available (for example, BLASTP).
  • Corresponding positions also can be based on structural alignments, for example, by using computer simulated alignments of protein structure.
  • amino acids of a polypeptide correspond to amino acids in a disclosed sequence refers to amino acids identified upon alignment of the polypeptide with the disclosed sequence to maximize identity or homology (where conserved amino acids are aligned) using a standard alignment algorithm, such as the GAP algorithm.
  • "at a position corresponding to” refers to a position of interest (e.g., base number or residue number) in a nucleic acid molecule or protein relative to the position in another reference nucleic acid molecule or protein.
  • the position of interest to the position in another reference protein can be in, for example, a precursor protein, an allelic variant, a heterologous protein, an amino acid sequence from the same protein of another species, and the like. Corresponding positions can be
  • identity between the sequences can be greater than 95%, greater than 96%, greater than 97%, greater than 98% and more particularly greater than 99%.
  • the position of interest is then given the number assigned in the reference nucleic acid molecule or polypeptide sequence.
  • amino acid residue 1 of the modified polypeptide corresponds to amino acid residue 1 of the unmodified CHC
  • amino acid residue 1 of the modified polypeptide corresponds to amino acid residue 1 of the unmodified CHC polypeptide.
  • nucleic acid molecule encompasses both deoxyribonucleotides and ribonucleotides and refers to a polymeric form of nucleotides including two or more nucleotide monomers.
  • the nucleotides can be naturally occurring, artificial (such as PNA and XNA), modified, and unusual nucleotides such as those referred to in 37 C.F.R. ⁇ 1 .821 -1 .822.
  • Examples of nucleic acid molecules include oligonucleotides that typically range in length from 2 nucleotides to about 100 nucleotides, and polynucleotides, which typically have a length greater than about 100 nucleotides.
  • homology for proteins can include conservative amino acid changes.
  • sequences of amino acids are aligned so that the highest order match is obtained (see, for example,:
  • sequence identity refers to the number of identical amino acids (homology includes conservative amino acid substitutions as well). Sequence identity can be determined by standard alignment algorithm programs, and used with default gap penalties established by each supplier. Substantially homologous nucleic acid molecules would hybridize typically at moderate stringency or at high stringency all along the length of the nucleic acid or along at least about 70%, 80% or 90% of the full length nucleic acid molecule of interest. Also contemplated are nucleic acid molecules that contain degenerate codons in place of codons in the hybridizing nucleic acid molecule. (For proteins, for determination of homology conservative amino acids can be aligned as well as identical amino acids; in this case percentage of identity and percentage homology vary).
  • nucleic acid molecules have nucleotide sequences that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical” can be determined using known computer algorithms such as the "FAST A "program,” using for example, the default parameters as in Pearson et al. Proc. Natl. Acad. Sci. USA 85: 2444 (1988) (other programs include the GCG program package (Devereux, J ., et al., Nucleic Acids Research 12(1 ): 387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S. F., et al., .1 . Molec. Biol.
  • Percent homology or identity of proteins and/ or nucleic acid molecules can be determined, for example, by comparing sequence information using a GAP computer program (e.g., Needleman et al. .1 . Mol. Biol. 48: 443 (1970), as revised by Smith and Waterman (Adv. Appl. Math. 2: 482 (1981 )).
  • a GAP program defines similarity as the number of aligned symbols (e.g., nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences.
  • Default parameters for the GAP program can include: (1 ) a unary comparison matrix (containing a value of 1 for identities and 0 for non identities) and the weighted comparison matrix of Gribskov et al. Nucl. Acids Res. 14: 6745 (1986), as described by Schwartz and Dayhoff, eds., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3 .0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps. Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide.
  • the term "at least 90% identical to” refers to percent identities from 90 to 100% relative to the reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polynucleotide length of 100 amino acids are compared, no more than 10% (i.e., 10 out of 100) of amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons can be made between a test and reference polynucleotides. Such differences can be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they can be clustered in one or more locations of varying length up to the maximum allowable, e.g. , 10/100 amino acid difference (approximately 90% identity).
  • Differences are defined as nucleic acid or amino acid substitutions, insertions or deletions. At the level of homologies or identities above about 85-90%, the result should be independent of the program and gap parameters set; such high levels of identity can be assessed readily, often without relying on software.
  • amino acid replacement refers to the replacement of one amino acid by another amino acid.
  • the replacement can be by a natural amino acid or non-natural amino acids.
  • one amino acid is replaced by another amino acid in a protein, the total number of amino acids in the protein is unchanged.
  • mutants in the context of single or multiple amino acid replacements, are those amino acids that, while different from the original, such as native, amino acid at a given amino acid position, can replace the native one at that position without introducing any measurable change in a particular protein activity.
  • a population of sets of nucleic acid molecules encoding a collection of mutant molecules is generated and phenotypically characterized such that proteins with sequences of amino acids different from the original amino acid, but that still elicit substantially the same level (i.e., at least 10%, 50%, 70%, 90%, 95%, 100%, depending upon the protein) and type of desired activity as the original protein are selected.
  • a naked polypeptide chain refers to a polypeptide that is not post-translationally modified or otherwise chemically modified, and only contains covalently linked amino acids.
  • a "polypeptide complex” includes polypeptides produced by chemical modification or post-translational modification. Such modifications include, but are not limited to, pegylation, albumination, glycosylation, famysylation, phosphorylation and/or other polypeptide modifications known in the art.
  • amino acids which occur in the various sequences of amino acids provided herein, are identified according to their known, three-letter or one-letter abbreviations.
  • non-natural amino acids refer to the 20 L-amino acids that occur in polypeptides.
  • non-natural amino acid refers to an organic compound that has a structure similar to a natural amino acid but has been modified structurally to mimic the structure and reactivity of a natural amino acid.
  • Non-naturally occurring amino acids thus, include amino acids or analogs of amino acids other than the 20 naturally-occurring amino acids and include, but are not limited to, the D-isostereomers of amino acids.
  • amino acid is an organic compound containing an amino group and a carboxylic acid group.
  • a polypeptide contains two or more amino acids.
  • amino acids include the twenty naturally-occurring amino acids non-natural amino acids, and amino acid analogs.
  • an amino acid residue is an amino acid molecule that has lost a hydrogen atom or a hydroxyl moiety by becoming joined to another amino acid molecule. When joined to two other molecules of amino acid(s), the residue has lost both a hydrogen atom and a hydroxyl moiety, thereby having lost a water molecule.
  • treatment is an approach for obtaining beneficial or desired clinical results.
  • beneficial or desired clinical results include, but are not limited to, one or more of the following: lessening severity, alleviation, and/or removal of one or more symptoms associated with cancer. Treatment also encompasses any pharmaceutical use of the modified CHC's and compositions provided herein.
  • an "effective amount" of drug, compound, or pharmaceutical composition is an amount sufficient to affect beneficial or desired results including clinical results, for example in the treatment of cancer.
  • An effective amount can be administered in one or more administrations.
  • an effective amount of drug, compound, or pharmaceutical composition is an amount sufficient to treat, ameliorate, reduce the intensity of and prevent cancer.
  • an effective amount of a drug, compound, or pharmaceutical composition may or may not be achieved when administered in conjunction with another drug, compound, or pharmaceutical composition.
  • an "effective amount" may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.
  • An "individual” is a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, farm animals (such as cows), sport animals, pets (such as cats, dogs and horses), primates, mice and rats.
  • pharmaceutically acceptable carrier includes any material which, when combined with an active ingredient, allows the ingredient to retain biological activity and is non-reactive with the subject's immune system.
  • Examples include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/water emulsion, and various types of wetting agents.
  • Preferred diluents for aerosol or parenteral administration are phosphate buffered saline or normal (0.9%) saline.
  • Compositions comprising such carriers are formulated by well known conventional methods (see, for example, Remington's Pharmaceutical Sciences, 18th edition, A. Gennaro, ed., Mack Publishing Co., Easton, PA, 1990; and Remington, The
  • the present invention is based on the discovery that localization of clathrin in the nucleus is preceded by its detrimerization in the cytosol, and that detrimerization is dependent on a topology switch near the center of the clathrin trimerization domain of the clathrin heavy chain.
  • This switch as illustrated in Figure 2, includes helix 7j, helix Tx1 and a segment, labeled pCS, which is predicted to undergo a conformational change.
  • cysteine-1573 in the Bos taurus clathrin having NCBI Reference Sequence Number NP_776448 is crucial for clathrin detrimerization and is key to the ability of clathrin hub to enter the nucleus.
  • This helix 7j cysteine is also numbered cysteine-1573 in the Homo sapiens clathrin heavy chain (CHC) having NCBI Reference Sequence Number NP_004850.1 (SEQ ID N0:1 ), a sequence having the same heavy chain numbering scheme as NP_776448 (SEQ ID N0:2) (the numbering scheme from NP_776448 is used throughout, unless otherwise specified).
  • cysteine-1573 in helix 7j of the topology switch plays an important role in detrimerizing clathrin in the cytosol, and is therefore important in the function of monomeric clathrin in p53-mediated cancer suppression.
  • modified clathrins that are characterized by a higher tendency to detrimerize and localize to the nucleus than naturally-occurring, wild-type (WT) clathrin.
  • WT wild-type
  • modified clathrins may be grouped into three categories, as measured by the number of cells in the sample exhibiting nuclear localization of a given modified clathrin: minimally localizing, having at least 25% but less than 50% of the cells exhibiting nuclear localization; moderately localizing, where at least 50% but less than 75% of the cells exhibit nuclear localization; and highly localizing, where at least 75% of the cells exhibit nuclear localization.
  • the modified clathrins are impaired in their ability to form trimers, for example as a result of amino acid replacement by means of mutagenesis. This can be achieved by subjecting clathrin to mutations in the topology switch illustrated in Figure 2, thereby changing one or more of the amino acids in the switch.
  • mutants those bearing mutations in helix 7j, in particular those where the cysteine residue labeled cysteine-1573 (Cys-1573) has been mutated to another amino acid, and in particular to an uncharged or hydrophobic amino acid. Also included are mutants where histidine-1589 (His-1589) is mutated to another amino acid.
  • modified CHC polypeptides including an amino acid sequence obtained by deletion, replacement, addition, or insertion of at least one amino acid residue of the topology switch of unmodified CHC polypeptide.
  • the modified CHC polypeptides provided herein include precursor forms and mature forms; modifications are described with respect to the mature form, but also include modified precursor polypeptides.
  • Corresponding positions on a particular polypeptide may be determined, for example, by alignment of unchanged residues.
  • Exemplary modified CHC polypeptides provided herein contain an amino acid replacement at the locus corresponding to amino acid position 1573 of human clathrin heavy chain compared to unmodified human clathrin heavy chain, where a human clathrin heavy chain comprises a sequence of amino acid residues as set forth in SEQ ID NO:1 .
  • Such modified polypeptides include proteins comprising the sequence of SEQ. ID. NO:1 where the Cys residue at the 1573 th position is replaced with any other amino acid residue except cysteine.
  • the amino acid residue replacing said Cys is selected from the group consisting of Ala, Val, Leu, lie, Met, Gin, Glu, Gly, His, Met, Ser, Thr, Trp, and Tyr.
  • An uncharged or hydrophobic residue such as Ala, Val, Leu, He, or Met, is preferred.
  • said Cys residue is replaced with an Ala residue.
  • the His residue at the locus corresponding to the 1589 th position of the amino acid sequence of SEQ ID NO:1 is replaced with any other amino acid residue except histidine.
  • the His residue at the 1589 th position is replaced with an uncharged or hydrophobic residue, such as Ala, Val, Leu, lie, or Met.
  • said His residue is replaced with an Ala residue.
  • the modified CHC polypeptides comprise an amino acid sequence of Formula (1 ):
  • Xi is an amino acid residue selected from the group consisting of Ala, Val, Leu, lie, Met, Gin, Glu, Gly, His, Met, Ser, Thr, Trp, and Tyr, (1 -1572) is a peptide chain including the first 1572 amino acid residues of the human CHC polypeptide counted from the N-terminal end or an analog thereof or derivative thereof, and (1574-1675) is a peptide chain including amino acid residues 1574 to 1675 of the human CHC, or an analog thereof or a derivative thereof.
  • Xi is selected from the group consisting of Ala, Val, Leu, lie, and Met.
  • allelic variants, species variants and isoforms of the polypeptide whose sequence is set forth in SEQ ID NO: 1 such polypeptides also can be modified at loci corresponding to those of the polypeptides exemplified herein.
  • modified CHC polypeptides comprise the amino acid sequence of Formula (2):
  • Xi is an amino acid residue selected from the group consisting of Ala, Val, Leu, lie, Met, Gin, Glu, Gly, His, Met, Ser, Thr, Trp, and Tyr,
  • (1 -1572) is a peptide chain including the first 1572 amino acid residues of human CHC counted from the N- terminal end or an analog thereof or derivative thereof
  • (1574-1588) is a peptide chain including amino acids 1574 to 1588 of human CHC or an analog thereof or a derivative thereof.
  • X 2 is an amino acid residue selected from the group consisting of Ala, Val, Leu, lie, Met, Gin, Glu, Gly, Cys, Met, Ser, Thr, Trp, and Tyr, and (1590- 1675) is a peptide chain consisting of amino acids 1590 to 1675 of human CHC or an analog thereof or a derivative thereof.
  • Xi and X 2 are each independently selected from the group consisting of Ala, Val, Leu, lie, and Met.
  • the modified CHC polypeptide is a naked polypeptide chain.
  • the polypeptide is a polypeptide complex further comprising post-translational modifications, such as glycosylated residues.
  • the polypeptide may include other modifications known in the art.
  • modified CHC polypeptide where the CHC is pegylated, albuminated, glycosylated, or has undergone other modifications. Also provided are modified CHC
  • polypeptides further having one or more pseudo-wild-type mutations.
  • pseudo-wild-type mutations include deletion, replacement, addition, insertion or a combination thereof of the amino acid residue(s) of an unmodified CHC.
  • nucleic acid molecules comprising polynucleotide sequences which code for a modified CHC polypeptide as described herein.
  • vectors comprising such polynucleotide sequences and host cells containing such nucleic acid molecules or vectors.
  • the modified CHC polypeptide may be produced by expressing a polynucleotide sequence encoding the modified CHC polypeptide in a suitable host cell by standard techniques.
  • the modified CHC polypeptide is either expressed directly or as a precursor molecule which has an N-terminal or C-terminal extension, such as a His-tag.
  • Polynucleotide sequences coding for the modified CHC polypeptide may be prepared synthetically by established standard methods, e.g. the phosphoramidite method with an automatic DNA synthesizer and/or by polymerase chain reaction (PCR).
  • a vector which is capable of replicating in a selected microorganism or host cell and which carries a
  • the recombinant vector may be an autonomously replicating vector, i.e., a vector which exists as an extra-chromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extra-chromosomal element, a mini- chromosome, or an artificial chromosome.
  • the vector may contain any means for assuring self-replication.
  • the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated.
  • a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.
  • the vector may be linear or closed circular plasmids and will preferably contain an element(s) that permits stable integration of the vector into the host cell's genome or autonomous replication of the vector in the cell independent of the genome.
  • the recombinant expression vector is capable of replicating in yeast. Examples of sequences which enable the vector to replicate in yeast are the yeast plasmid 2 urn replication genes REP 1 -3 and origin of replication.
  • the vectors may contain one or more selectable markers which permit easy selection of transformed cells.
  • a selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.
  • Examples of bacterial selectable markers are the dal genes from Bacillus subtilis or Bacillus licheniformis, or markers which confer antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance.
  • Selectable markers for use in a filamentous fungal host cell include amdS (acetamidase), argB (ornithine carbamoyltransferase), pyrG
  • yeast host cells ADE2, HIS3, LEU2, LYS2, MET3, TRP1 , and URA3.
  • a well suited selectable marker for yeast is the Schizosaccharomyces pombe TPI gene (Russell (1985) Gene 40:125-130).
  • the polynucleotide sequence is operably connected to a suitable promoter sequence.
  • the promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intra-cellular polypeptides either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription in a bacterial host cell, are the promoters obtained from the E.
  • Streptomyces coelicolor agarase gene (dagA), Bacillus subtilis levansucrase gene (sacB), Bacillus licheniformis alpha-amylase gene (amyL), Bacillus stearothermophilus maltogenic amylase gene (amyM), Bacillus amyloliquefaciens alpha-amylase gene (amyQ), and Bacillus licheniformis penicillinase gene (penP).
  • suitable promoters for directing the transcription in a filamentous fungal host cell are promoters obtained from the genes for Aspergillus oryzae TAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus niger neutral alpha-amylase, and Aspergillus niger acid stable alpha-amylase.
  • useful promoters are the Saccharomyces cerevisiae Mai, TPI, ADH or PGK promoters.
  • the polynucleotide construct will also typically be operably connected to a suitable terminator.
  • yeast a suitable terminator is the TPI terminator (Alber ei al. (1982) J. Mol. Appl. Genet. 1 :419-434).
  • the procedures used to ligate the polynucleotide sequence, the promoter and the terminator, respectively, and to insert them into a suitable vector containing the information necessary for replication in the selected host are well known to those skilled in the art. It will be understood that the vector may be constructed either by first preparing a DNA construct containing the entire DNA sequence encoding a modified CHC polypeptide as described herein, and subsequently inserting this fragment into a suitable expression vector, or by sequentially inserting DNA fragments containing genetic information for individual elements of the CHC followed by ligation.
  • recombinant host cells comprising a polynucleotide sequence encoding a modified CHC polypeptide as described herein.
  • a vector comprising such polynucleotide sequence is introduced into the host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra- chromosomal vector as described earlier.
  • the host cell may be a unicellular microorganism, e.g., a prokaryote, or a non-unicellular microorganism, e.g., a eukaryote.
  • Example host cells include bacterial cells, insect cells, mammalian cells, plant cells, and yeast cells.
  • compositions comprising a modified CHC polypeptide as described herein can be used in the treatment of conditions which are sensitive to p53-mediated transactivation, such as cancer. Due to their impaired ability to form trimers, the modified CHC polypeptides as described herein can be administered as therapeutic agents without substantially interfering with the formation of vesicles for intercellular transport or other functions of WT clathrin.
  • the optimal dose level for any patient will depend on a variety of factors including the efficacy of the specific modified CHC polypeptide as described herein employed, the age, body weight, physical activity, and diet of the patient, on a possible combination with other drugs, and on the severity of the condition to be treated. It is recommended that the daily dosage of a composition be determined for each individual patient by those skilled in the art in a clinical setting.
  • compositions of a modified CHC polypeptide as described herein may contain adjuvants and additives typical of pharmaceutical formulations and are usually formulated as an aqueous solution.
  • the aqueous medium may be made isotonic, for example, with sodium chloride, sodium acetate or glycerol.
  • the aqueous medium may contain pH-adjusting additives such as buffers, and preservatives. Consequently, there is also provided a pharmaceutical composition comprising a modified CHC polypeptide as described herein and optionally one or more agents suitable for stabilization, preservation or isotonicity, for example, transition metal ions, phenol, cresol, a parabene, sodium chloride, glycerol or mannitol.
  • the pH-adjusting agent used in the pharmaceutical composition may be a buffer selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and
  • tris(hydroxymethyl)-aminomethan bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid or mixtures thereof.
  • the pharmaceutically acceptable preservative may be selected from the group consisting of phenol, o-cresol, m-cresol, p-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p-hydroxybenzoate, 2- phenylethanol, benzyl alcohol, chlorobutanol, and thiomerosal, bronopol, benzoic acid, imidurea, chlorohexidine, sodium dehydroacetate, chlorocresol, ethyl p- hydroxybenzoate, benzethonium chloride, chlorphenesine (3p- chlorphenoxypropane-1 ,2-diol) or mixtures thereof.
  • the preservative is present in a concentration from 0.1 mg/ml to 20 mg/ml. In some instances, the preservative is present in a concentration from 0.1 mg/ml to 5 mg/ml. In other instances, the preservative is present in a concentration from 5 mg/ml to 10 mg/ml. In further instances, the preservative is present in a concentration from 10 mg/ml to 20 mg/ml.
  • the use of a preservative in pharmaceutical compositions is well-known to the skilled person. For convenience, reference is made to Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
  • the isotonicity agent may be selected from the group consisting of a salt (e.g. sodium chloride), a sugar or sugar alcohol, an amino acid (e.g. L-glycine, L- histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine), an alditol (e.g. glycerol (glycerine), 1 ,2-propanediol (propyleneglycol), 1 ,3-propanediol, 1 ,3- butanediol) polyethyleneglycol (e.g. PEG400), or mixtures thereof.
  • a salt e.g. sodium chloride
  • a sugar or sugar alcohol e.g. L-glycine, L- histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine
  • an alditol e.g
  • Any sugar such as mono-, di-, or polysaccharides, or water-soluble glucans, including for example fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch and carboxymethylcellulose-Na may be used.
  • compositions include suitable delivery forms known in the art including, but not limited to, carriers such as liposomes. See, for example, Mahato et al. (1997) Pharm. Res. 14:853-859.
  • Liposomal preparations include, but are not limited to, cytofectins, multilamellar vesicles and unilamellar vesicles.
  • more than one modified CHC as described herein may be administered, for example in compositions that may contain at least one, at least two, at least three, at least four, at least five different modified CHC polypeptides.
  • a mixture of modified CHC polypeptides may be particularly useful in treating a broader range of population of individuals.
  • a polynucleotide encoding a modified CHC polypeptide as described herein may also be used for delivery and expression of any of said polypeptides in a desired cell.
  • an expression vector can be used to direct expression of a modified CHC polypeptides according to methods known in the art.
  • the expression vector can be administered by any means known in the art, such as intraperitoneally, intravenously, intramuscularly, subcutaneously, intrathecally, intraventricularly, orally, enterally, parenterally, intranasally, dermally, sublingually, or by inhalation.
  • administration of expression vectors includes local or systemic administration, including injection, oral administration, particle gun or catheterized administration, and topical administration.
  • One skilled in the art is familiar with administration of expression vectors to obtain expression of an exogenous protein in vivo. See, e.g., U.S. Patent Nos. 6,436,908; 6,413,942; and 6,376,471 .
  • Targeted delivery of therapeutic compositions comprising a nucleic acid molecule encoding a modified CHC polypeptide as described herein can also be used.
  • Receptor-mediated DNA delivery techniques are described in, for example, Findeis et al., Trends Biotechnol. (1993) 1 1 :202; Chiou et al., Gene Therapeutics: Methods And Applications Of Direct Gene Transfer (J. A. Wolff, ed.) (1994); Wu et al., J. Biol Chem. (1988) 263:621 ; Wu et al., J. Biol. Chem. (1994) 269:542; Zenke et al., Proc. Natl. Acad.
  • compositions containing a polynucleotide are administered in a range of about 100 ng to about 200 mg of DNA for local administration in a gene therapy protocol. Concentration ranges of about 500 ng to about 50 mg, about 1 ⁇ g to about 2 mg, about 5 ⁇ g to about 500 ⁇ g, and about 20 ⁇ g to about 100 ⁇ g of DNA can also be used during a gene therapy protocol.
  • the therapeutic polynucleotides of the present invention can be delivered using gene delivery vehicles.
  • the gene delivery vehicle can be of viral or non- viral origin (see generally, Jolly, Cancer Gene Therapy (1994) 1 :51 ; Kimura, Human Gene Therapy (1994) 5:845; Connelly, Human Gene Therapy (1995) 1 :185; and Kaplitt, Nature Genetics (1994) 6:148). Expression of such coding sequences can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence can be either constitutive or regulated.
  • Viral-based vectors for delivery of a desired polynucleotide and expression in a desired cell are well known in the art.
  • Exemplary viral-based vehicles include, but are not limited to, recombinant retroviruses (see, e.g., PCT Publication Nos. WO 90/07936; WO 94/03622; WO 93/25698; WO 93/25234; WO 93/1 1230; WO 93/10218; WO 91/02805; U.S. Patent Nos. 5,219,740; 4,777,127; GB Patent No. 2,200,651 ; and EP Patent No.
  • alphavirus-based vectors e.g., Sindbis virus vectors, Semliki forest virus (ATCC VR-67; ATCC VR-1247), Ross River virus (ATCC VR-373; ATCC VR-1246) and Venezuelan equine encephalitis virus (ATCC VR-923; ATCC VR-1250; ATCC VR 1249; ATCC VR- 532)
  • AAV adeno-associated virus
  • Non-viral delivery vehicles and methods can also be employed, including, but not limited to, polycationic condensed DNA linked or unlinked to killed adenovirus alone (see, e.g., Curiel, Hum. Gene Ther. (1992) 3:147); ligand-linked DNA(see, e.g., Wu5 J. Biol. Chem. (1989) 264:16985); eukaryotic cell-delivery vehicles cells (see, e.g., U.S. Patent No. 5,814,482; PCT Publication Nos. WO 95/07994; WO 96/17072; WO 95/30763; and WO 97/42338) and nucleic charge neutralization or fusion with cell membranes.
  • polycationic condensed DNA linked or unlinked to killed adenovirus alone see, e.g., Curiel, Hum. Gene Ther. (1992) 3:147
  • ligand-linked DNA see, e.g., Wu5 J. Biol. Chem. (1989
  • Naked DNA can also be employed.
  • Exemplary naked DNA introduction methods are described in PCT Publication No. WO 90/1 1092 and U.S. Patent No. 5,580,859.
  • Liposomes that can act as gene delivery vehicles are described in U.S. Patent No. 5,422, 120; PCT Publication Nos. WO 95/13796; WO 94/23697; WO 91/14445; and EP Patent NO. 0 524 968.
  • a modified CHC polypeptide is included as active compound in a pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect.
  • the therapeutically effective concentration can be determined empirically by testing the compounds in known in vitro and in vivo systems.
  • the active compounds can be administered by any appropriate route, for example, orally, nasally, pulmonarily, parenterally, intravenously, intradermally,
  • the modified CHC polypeptide and physiologically acceptable salts and solvates thereof can be formulated for administration by inhalation (either through the mouth or the nose), oral, pulmonary, transdermal, parenteral or rectal administration.
  • the modified CHC can be delivered in the form of an aerosol spray from pressurized packs or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit can be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator can be
  • the modified CHC can be delivered in the form of an aerosol spray from a nebulizer, turbonebulizer, or microprocessor-controlled metered dose oral inhaler with the use of a suitable propellant.
  • a suitable propellant usually, the particle size of the aerosol spray is small, such as in the range of 0.5 to 5 microns.
  • detergent surfactants are not typically used.
  • the modified CHC polypeptide can be formulated as a depot preparation.
  • Such long-acting formulations can be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
  • the therapeutic compounds can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil), ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the modified CHC polypeptide can be formulated for parenteral administration by injection (e.g., by bolus injection or continuous infusion).
  • Formulations for injection can be presented in unit dosage form (e.g., in ampoules or in multi-dose containers) with an added preservative.
  • the compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient can be in powder-lyophilized form for constitution with a suitable vehicle, e.g., sterile pyrogen free water, before use.
  • the modified CHC polypeptide can also be formulated for local or topical application, such as for topical application to the skin (transdermal) and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracistemal or intraspinal application.
  • solutions particularly those intended for ophthalmic use, can be formulated as 0.01 %-10% isotonic solutions and pH about 5-7 with appropriate salts.
  • the compounds can be formulated as aerosols for topical application, such as by inhalation.
  • the concentration of active compound in a pharmaceutical composition depends on absorption, inactivation and excretion rates of the active compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art.
  • the pharmaceutical compositions can be presented in a package, in a kit or dispenser device, that can contain one or more unit dosage forms containing the active ingredient.
  • the package for example, contains metal or plastic foil, such as a blister pack.
  • the pack or dispenser device can be
  • compositions containing the active agents can be packaged as articles of manufacture containing packaging material, an agent provided herein, and a label that indicates the disorder for which the agent is provided.
  • the pharmaceutical compositions can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. , pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. , lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g. , potato starch or sodium starch glycolate); or Wetting agents (e.g. , sodium lauryl sulphate).
  • binding agents e.g. , pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. , lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g., magnesium stearate, talc or silica
  • disintegrants e.
  • administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with Water or other suitable vehicle before use.
  • Such liquid preparations can be prepared by
  • suspending agents e.g. , sorbitol syrup, cellulose derivatives or hydrogenated edible fats
  • emulsifying agents e.g. , lecithin or acacia
  • non aqueous vehicles e.g. , almond oil, oily esters, ethyl alcohol or fractionated vegetable oils
  • preservatives e.g. , methyl or propyl p hydroxybenzoates or sorbic acid
  • the preparations also can contain buffer salts, flavoring, coloring and/or sweetening agents as appropriate.
  • nucleic acid molecules encoding the modified CHC polypeptide and expression vectors encoding them that are suitable for gene therapy.
  • nucleic acid molecules can be administered in vivo (e.g., systemically or by other routes), or ex vivo, such as by removal of cells, including lymphocytes, introduction of the nucleic acid molecule therein, and reintroduction into the host or a compatible recipient.
  • modified CHC polypeptide can be delivered to cells and tissues by expression of nucleic acid molecules.
  • the modified CHC polypeptide can be administered as nucleic acid molecules encoding the CHC polypeptide, including ex vivo techniques and direct in vivo expression.
  • Nucleic acid molecules can be delivered to cells and tissues by any method known to those of skill in the art.
  • the isolated nucleic acid molecules can be incorporated into vectors for further manipulation.
  • vector or plasmid refers to discrete elements that are used to introduce heterologous DNA into cells for either expression or replication thereof.
  • Methods for administering modified CHC polypeptide by expression of encoding nucleic acid molecules include administration of recombinant vectors.
  • the vector can be designed to remain episomal, such as by inclusion of an origin of replication or can be designed to integrate into a chromosome in the cell.
  • Modified CHC polypeptides also can be used in ex vivo gene expression therapy using non-viral vectors.
  • cells can be engineered to express a modified CHC polypeptide, such as by integrating a modified CHC encoding nucleic acid molecule into a genomic location, either operatively linked to regulatory sequences or such that it is placed operatively linked to regulatory sequences in a genomic location.
  • a modified CHC polypeptide such as by integrating a modified CHC encoding nucleic acid molecule into a genomic location, either operatively linked to regulatory sequences or such that it is placed operatively linked to regulatory sequences in a genomic location.
  • Such cells then can be administered locally or systemically to a subject, such as a patient in need of treatment.
  • Viral vectors include, for example adenoviruses, herpes viruses, retroviruses and others designed for gene therapy can be employed.
  • the vectors can remain episomal or can integrate into chromosomes of the treated subject.
  • a modified CHC polypeptide can be expressed by a virus, which is administered to a subject in need of treatment.
  • Virus vectors suitable for gene therapy include adenovirus, adeno-associated virus, retroviruses, lentiviruses and others noted above.
  • adenovirus expression technology is well-known in the art and adenovirus production and administration methods also are well known.
  • Adenovirus serotypes are available, for example, from the American Type Culture Collection (ATCC, Rockville, MD).
  • Adenovirus can be used ex vivo.
  • cells are isolated from a patient in need of treatment, and transduced with a modified CHC polypeptide-expressing adenovirus vector. After a suitable culturing period, the transduced cells are administered to a subject locally and/or systemically.
  • modified CHC polypeptide-expressing adenovirus particles are isolated and formulated in a pharmaceutically-acceptable carrier for delivery of a therapeutically effective amount to prevent, treat or ameliorate a disease or condition of a subject.
  • a nucleic acid molecule source with an agent that targets cells, such as an antibody specific for a cell surface membrane protein or a target cell, or a ligand for a receptor on a target cell.
  • the nucleic acid molecules can be introduced into artificial chromosomes and other non-viral vectors.
  • Artificial chromosomes such as ACES (see,
  • MACs mammalian artificial chromosomes
  • MACs mammalian artificial chromosomes
  • ACE mammalian satellite DNA-based Artificial Chromosome Expression
  • Purified mammalian ACEs can then be re-introduced into a variety of recipient cell lines where they have been stably maintained for extended periods in the absence of selective pressure using an ACE System. Using this approach, specific loading of one or two gene targets has been achieved in LMTK(— ) and CHO cells.
  • a two-step gene replacement technique in yeast, starting with a complete adenovirus genome (Ad2; Ketner et al. Proc. Natl. Acad. Sci. USA 91 : 6186-6190 61 (1994)) cloned in a Yeast Artificial Chromosome (YAC) and a plasmid containing adenovirus sequences to target a specific region in the YAC clone, an expression cassette for the gene of interest and a positive and negative selectable marker.
  • YAC Yeast Artificial Chromosome
  • the nucleic acids encoding the modified CHC polypeptides can be encapsulated in a vehicle, such as a liposome, or introduced into a cell, such as a bacterial cell, particularly an attenuated bacterium or introduced into a viral vector.
  • a vehicle such as a liposome
  • proteins that bind to a cell surface membrane protein associated with endocytosis can be used for targeting and/or to facilitate uptake, e.g., capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, and proteins that target intracellular localization and enhance intracellular half-life.
  • nucleic acid molecules encoding the modified CHC polypeptides are introduced into cells that are from a suitable donor or the subject to be treated.
  • Cells into which a nucleic acid molecule can be introduced for purposes of therapy include, for example, any desired, available cell type appropriate for the disease or condition to be treated, including but not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., such as stem cells obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, and other sources thereof.
  • nucleic acid is introduced into these isolated cells and the modified cells are administered to the subject.
  • Treatment includes direct administration, such as, for example, encapsulated within porous membranes, which are implanted into the patient.
  • Techniques suitable for the transfer of nucleic acid into mammalian cells in vitro include the use of liposomes and cationic lipids (e.g., DOTMA, DOPE and DCChol) electroporation, microinjection, cell fusion, DEAE-dextran, and calcium phosphate precipitation methods.
  • Methods of DNA delivery can be used to express modified CHC polypeptides in vivo. Such methods include liposome delivery of nucleic acids and naked DNA delivery, including local and systemic delivery such as using
  • electroporation ultrasound and calcium-phosphate delivery.
  • Other techniques include microinjection, cell fusion, chromosome-mediated gene transfer, microcell- mediated gene transfer and spheroplast fusion.
  • a modified CHC polypeptide can be linked to expression of additional molecules.
  • expression of a modified CHC polypeptide can be linked with expression of a cytotoxic product such as in an engineered virus or expressed in a cytotoxic virus.
  • a cytotoxic product such as in an engineered virus or expressed in a cytotoxic virus.
  • viruses can be targeted to a particular cell type that is a target for a therapeutic effect.
  • the expressed modified CHC polypeptide can be used to enhance the cytotoxicity of the virus.
  • In vivo expression of a modified CHC polypeptide can include operatively linking a modified CHC polypeptide encoding nucleic acid molecule to specific regulatory sequences such as a cell-specific or tissue-specific promoter.
  • Modified CHC polypeptides also can be expressed from vectors that specifically infect and/ or replicate in target cell types and/or tissues. Inducible promoters can be use to selectively regulate modified CHC polypeptide expression.
  • Nucleic acid molecules in the form of naked nucleic acids or in vectors, artificial chromosomes, liposomes and other vehicles can be administered to the subject by systemic administration, topical, local and other routes of administration.
  • the nucleic acid molecule or vehicle containing the nucleic acid molecule can be targeted to a cell.
  • Administration also can be direct, such as by administration of a vector or cells that typically targets a cell or tissue.
  • tumor cells and proliferating can be targeted cells for in vivo expression of modified CHC polypeptides.
  • Cells used for in vivo expression of a modified CHC polypeptide also include cells autologous to the patient. These cells can be removed from a patient, nucleic acids for expression of a modified CHC polypeptide introduced, and then administered to a patient such as by injection or engraftment.
  • Polynucleotides and expression vectors provided herein can be made by any suitable method. Further provided are nucleic acid vectors containing nucleic acid molecules as described above, including a nucleic acid molecule containing a sequence of nucleotides that encodes the polypeptide as set forth in any of SEQ ID NOS: 3-4 or a functional fragment thereof. Further provided are nucleic acid vectors containing nucleic acid molecules as described above and cells containing these vectors.
  • modified CHC polypeptides and nucleic acid molecules provided herein can be used for treatment of any condition for which p53-mediated transactivation is employed.
  • This section provides exemplary uses of modified CHC polypeptides and administration methods. Such methods include, but are not limited to, methods of treatment of physiological and medical conditions described and listed below.
  • the modified CHC polypeptides are intended for use in therapeutic methods for the treatment of cancer.
  • cancers include bladder cancer, brain cancer, head and neck cancer, kidney cancer, lung cancers such as small cell lung cancer and non-small cell lung cancer, myeloma, neuroblastoma/glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, colon cancer, cervical carcinoma, breast cancer, and leukemias.
  • the modified CHC's are especially well suited for treatment of solid tumors and advanced cancers which cannot be treated by most conventional cancer therapies.
  • the modified CHC polypeptides and nucleic acid molecules encoding modified CHC polypeptides also can be
  • Treatment of diseases and conditions with modified CHC polypeptides can be effected by any suitable route of administration using suitable formulations as described herein, including but not limited to, subcutaneous injection, oral, nasal, pulmonary and transdermal administration. If necessary, a particular dosage and duration and treatment protocol can be empirically determined or extrapolated. For example, exemplary doses of modified CHC polypeptides can be used as a starting point to determine appropriate dosages. Particular dosages and regimens can be empirically determined.
  • Dosage levels would be apparent to one of skill in the art and would be determined based on a variety of factors, such as body weight of the individual, general health, age, the activity of the specific compound employed, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease or condition, and the subject's disposition to the disease/condition and the judgment of the treating physician.
  • the amount of active ingredient that can be combined with the carrier materials to produce a single dosage form with vary depending upon the subject treated and the particular mode of administration.
  • a maintenance dose of a compound or composition provided herein can be administered, if necessary; and the dosage, the dosage form, or frequency of administration, or a combination thereof, can be varied.
  • the subject can require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
  • Administration of a modified CHC polypeptide in accordance with the methods of the present invention can be continuous or intermittent, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners.
  • the administration of may be essentially continuous over a
  • preselected period of time may be in a series of spaced dosages, e.g., either before, during, or after the insurgence of cancers.
  • any of the modified CHC polypeptides provided herein for the manufacture of a medicament for treating of a subject having cancer.
  • cancers include by way of example bladder cancer, brain cancer, head and neck cancer, kidney cancer, lung cancers such as small cell lung cancer and non-small cell lung cancer, myeloma, neuroblastoma/glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, colon cancer, cervical carcinoma, breast cancer, and leukemias.
  • CTXD clathrin fragment
  • Figure 1 A clathrin fragment capable of trimerization (Figure 1 ) that complemented previously solved domains of clathrin was synthesized [10, 33].
  • the CTXD construct did not have a light chain- binding site and featured two point mutations (C1528A and T1585L) to increase protein stability and solubility. At first, the quality of CTXD crystals was
  • the CTXD structure also suggests the long tripod helices, which have been modeled previously as straight and rigid [13, 15], have bends in the CTXD structure. It is not believed these bends are the result of model building bias because Rf ree worsens when they are made straight. After glutamate-1624, the long helix abruptly changes direction, but the remaining 30 residues (1625-1654) could not be built because of weak electron density.
  • This C- terminal region contains the i638QLMLTi 642 sequence that closely resembles the consensus sequence [35] that binds the uncoating ATPase Hsc70 [36].
  • helix 7j is shifted away from 1590N IMDFAMP-1597 (see arrow, Figure 2A) towards helix 7h (residue 1532-1544). Helix 7j is displaced by approximately 10 A relative to the grey helix in Figure 2A taken from assembled clathrin (PDB code 1 X14).
  • helix 7j from the clathrin hub [13] lies in between the indicated helices in Figure 2A.
  • PDB code 3LVG clathrin hub
  • glycine-1567 is positioned near the middle of helix 7j, which is noteworthy because glycine is known to be a helix breaker [45].
  • the assembled clathrin and clathrin hub models are both saturated with light chains, but CTXD does not have any.
  • helix 7j is offset a distance approximately equal to the diameter of a helix raises the possibility that the position of helix 7j is subject to the light chain. This suggestion is supported by the observation that C-terminal segments of the light chain are close to helix 7j [13].
  • the structural components in Figure 2 are conserved in lower and higher invertebrates and vertebrates, suggesting they may be relevant for function.
  • Clathrin participates in activating cancer suppressor p53 in the nucleus when clathrin is made monomeric [31 ].
  • non-cancer (HEK293T) and cancer (HeLa, H1299, and MCF7) cells were transfected with human influenza hemagglutinin (HA)-tagged WT trimeric hub or with HA-C1573A hub and observed by means of confocal microscopy.
  • HA hemagglutinin
  • the ability of clathrin hub to enter the nucleus clearly depends on cysteine-1573 (Figure 3). In all cell types tested, the nuclear localization of clathrin hub significantly increases when cysteine-1573 is changed to alanine, compared to WT ( Figure 3A).
  • the structure of the trimerization domain illustrated herein shows cysteine-1573 is located in helix 7j, which is part of a topology switch that includes the 1590N IMDFAM P-1597 segment that is predicted to undergo a conformational change.
  • the evolutionarily conserved components in Figure 2 are uniquely organized to form a chain of interfaces that connect legs together in the trimerization domain.
  • Microscopy data show HA-tagged WT hub is exclusively
  • DLS data indicate the mean particle size of clathrin hub is reduced by -20% when cysteine-1573 in helix 7j is replaced with alanine.
  • aAverages and standard deviations were determined from 3 independent experiments for each construct. 1 nm equals 10 "9 meters.
  • compositions and methods by way of example and not by way of limitation. This description clearly enables one skilled in the art to make and use the compositions and methods as described herein, and describes several embodiments, adaptations, variations, alternatives and uses thereof. Additionally, it is to be understood that the compositions and methods are not limited in their application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. Other embodiments may be practiced or carried out in various ways. Also, it will be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting.
  • Rosetta 2(DE3) plysS cells with CTXD were grown at 37 °C in LB and induced at 30 °C with IPTG.
  • Cell pellets were resuspended and sonicated in cold lysis buffer (10 mM Na 2 HP0 4 , 10 mM imidazole, 0.5 M NaCI, pH 7.4 with Triton X-100, ⁇ -mercaptoethanol, and protease inhibitors). Crude lysate was passed through a metal affinity column (GE Healthcare), and a POROS 20 HQ anion-exchange column (Perseptive Biosystems) at 4 °C
  • a data set was collected at 100 °K in 0.3° oscillations using a NOIR-1 CCD detector at the MBC 4.2.2 beamline at the Advanced Light Source, Lawrence Berkeley National Laboratory. Data were processed using HKL2000.
  • FIG. 1 left, domain map of three identical heavy chain legs (A, B, and C) of clathrin: NTD, N-terminal domain; DD, distal domain; PD, proximal domain (light chain binding); CTXD, trimerization domain.
  • CTXD construct (aa1521 -1654, red bar) with an N-terminal histidine-tag associates into a trimer.
  • Right, green leg C (numbered 1 -1624) is tilted down and away from the two grey legs. Histidine tags are visible in legs A and C, but not leg B.
  • Residues 1625-1654 were not modeled, but packing of 24 protomers in the asymmetric unit leaves room for them.
  • Asterisk indicates unfolded helix 7g in the green colored leg (this helix is also disordered in the other two legs).
  • FIG. 2A Helix 7j (magenta) and predicted conformational switch (pCS, colored red) in Leg B (PDB 3QIL, salmon color) is compared to the same structures in PDB 1 X14 [15] (green) and PDB 3LVG [13] (blue, only Helix 7j shown for clarity).
  • a one-turn helix (Tx2 in 1 X14, colored green) is unfolded in 3QIL (red strand).
  • Top view shows the spatial arrangement of Helix 7j, Tx1 , and pCS (color coding the same as in A).
  • Cysteine-1573 (pale teal) is adjacent to pCS marked by histidine-1589 (salmon, asterisk in D).
  • C Switch model shows how molecular contacts between pCS (red) and Tx1 (yellow) in the next leg over are mediated by helix 7j/pCS interactions (curved arrows). The numbers refer to the sequence that releases a leg. Two switches must be activated to release one monomer.
  • D The putative topology switch is conserved in lower and higher vertebrates and invertebrates.
  • Cysteine- 1573 (teal star) is almost entirely conserved compared to other cysteines (black diamonds) in this helix (note: the human clathrin sequence NP_004850.1 in the sequence alignment has a different numbering scheme than the bovine clathrin sequence).
  • MCF7 (breast cancer) cells were maintained in MEM with 10% FBS, 100 U penicillin/100 ⁇ g streptomycin, 2 mM glutamine, 1 mM sodium pyruvate, 0.1 % sodium bicarbonate, and 120 ng/ml insulin (Sigma).
  • HA signal is present in the cytoplasmic fractions of both HA-hub WT and HA-hub C1573A, as well as in the nuclear fraction of cells expressing HA-hub C1573A, but not HA-hub WT.
  • b-arrestin acts as a clathrin adaptor in endocytosis of the b2-adrenergic receptor. Nature 383, 447-450.
  • Atomic structure of clathrin A b propeller terminal domain joins an a zigzag linker. Cell 95, 563-573.
  • Clathrin light chains LCa and LCb are similar, polymorphic, and share repeated heptad motifs. Science 236, 320-324. 18. Brodsky, F. M., Hill, B. L, Acton, S. L, Nathke, I., Wong, D. H.,
  • HIP1 Huntingtin-interacting protein 1
  • Section D Biological Crystallography 54, 905-21 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des dérivés de clathrine se concentrant dans le noyau et des procédés d'utilisation de ces dérivés dans le traitement du cancer.
PCT/US2012/051369 2011-08-23 2012-08-17 Compositions et procédés pour traiter le cancer WO2013028527A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161526392P 2011-08-23 2011-08-23
US61/526,392 2011-08-23

Publications (1)

Publication Number Publication Date
WO2013028527A1 true WO2013028527A1 (fr) 2013-02-28

Family

ID=46785809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/051369 WO2013028527A1 (fr) 2011-08-23 2012-08-17 Compositions et procédés pour traiter le cancer

Country Status (1)

Country Link
WO (1) WO2013028527A1 (fr)

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2200651A (en) 1987-02-07 1988-08-10 Al Sumidaie Ayad Mohamed Khala A method of obtaining a retrovirus-containing fraction from retrovirus-containing cells
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
EP0345242A2 (fr) 1988-06-03 1989-12-06 Smithkline Biologicals S.A. Expression de protéines gag de rétrovirus dans les cellules eucaryotes
WO1990007936A1 (fr) 1989-01-23 1990-07-26 Chiron Corporation Therapies de recombinaison pour infections et troubles hyperproliferatifs
WO1990011092A1 (fr) 1989-03-21 1990-10-04 Vical, Inc. Expression de sequences de polynucleotides exogenes chez un vertebre
WO1991002805A2 (fr) 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
WO1991014445A1 (fr) 1990-03-21 1991-10-03 Research Development Foundation Liposomes heterovesiculaires
WO1993003769A1 (fr) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Transfert induit par adenovirus de genes vers la voie gastro-intestinale
WO1993010218A1 (fr) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs
WO1993011230A1 (fr) 1991-12-02 1993-06-10 Dynal As Cellule souche modifiee de mammifere bloquant la replication virale
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1993019191A1 (fr) 1992-03-16 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des cytokines pour traitement antitumoral
WO1993025234A1 (fr) 1992-06-08 1993-12-23 The Regents Of The University Of California Procedes et compositions permettant de cibler des tissus specifiques
WO1993025698A1 (fr) 1992-06-10 1993-12-23 The United States Government As Represented By The Particules vecteurs resistantes a l'inactivation par le serum humain
WO1994003622A1 (fr) 1992-07-31 1994-02-17 Imperial College Of Science, Technology & Medicine Vecteurs retroviraux du type d, bases sur le virus du singe mason-pfizer
WO1994012649A2 (fr) 1992-12-03 1994-06-09 Genzyme Corporation Therapie genique de la fibrose kystique
WO1994023697A1 (fr) 1993-04-22 1994-10-27 Depotech Corporation Liposomes de cyclodextrine encapsulant des composes pharmacologiques et leurs procedes d'utilisation
WO1994028938A1 (fr) 1993-06-07 1994-12-22 The Regents Of The University Of Michigan Vecteurs d'adenovirus pour therapie genique
WO1995000655A1 (fr) 1993-06-24 1995-01-05 Mc Master University Vecteurs a base d'adenovirus destines a la therapie genique
WO1995007994A2 (fr) 1993-09-15 1995-03-23 Viagene, Inc. Vecteurs composes d'alphavirus recombinants
WO1995011984A2 (fr) 1993-10-25 1995-05-04 Canji, Inc. Vecteur recombinant d'adenovirus et procedes d'utilisation
WO1995013796A1 (fr) 1993-11-16 1995-05-26 Depotech Corporation Vesicules a taux controle de liberation des principes actifs
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
WO1995030763A2 (fr) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Vecteurs retroviraux a taux de recombinaison reduit
WO1996017072A2 (fr) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Vecteurs d'alphavirus de recombinaison
US5580859A (en) 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
WO1997042338A1 (fr) 1996-05-06 1997-11-13 Chiron Corporation Vecteurs retroviraux sans croisement
US5814482A (en) 1993-09-15 1998-09-29 Dubensky, Jr.; Thomas W. Eukaryotic layered vector initiation systems
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6413942B1 (en) 1989-03-21 2002-07-02 Vical, Inc. Methods of delivering a physiologically active polypeptide to a mammal
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function

Patent Citations (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB2200651A (en) 1987-02-07 1988-08-10 Al Sumidaie Ayad Mohamed Khala A method of obtaining a retrovirus-containing fraction from retrovirus-containing cells
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
EP0345242A2 (fr) 1988-06-03 1989-12-06 Smithkline Biologicals S.A. Expression de protéines gag de rétrovirus dans les cellules eucaryotes
WO1990007936A1 (fr) 1989-01-23 1990-07-26 Chiron Corporation Therapies de recombinaison pour infections et troubles hyperproliferatifs
WO1990011092A1 (fr) 1989-03-21 1990-10-04 Vical, Inc. Expression de sequences de polynucleotides exogenes chez un vertebre
US5580859A (en) 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US6413942B1 (en) 1989-03-21 2002-07-02 Vical, Inc. Methods of delivering a physiologically active polypeptide to a mammal
WO1991002805A2 (fr) 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
WO1991014445A1 (fr) 1990-03-21 1991-10-03 Research Development Foundation Liposomes heterovesiculaires
EP0524968A1 (fr) 1990-03-21 1993-02-03 Res Dev Foundation Liposomes heterovesiculaires.
WO1993003769A1 (fr) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Transfert induit par adenovirus de genes vers la voie gastro-intestinale
WO1993010218A1 (fr) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs
WO1993011230A1 (fr) 1991-12-02 1993-06-10 Dynal As Cellule souche modifiee de mammifere bloquant la replication virale
WO1993019191A1 (fr) 1992-03-16 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des cytokines pour traitement antitumoral
WO1993025234A1 (fr) 1992-06-08 1993-12-23 The Regents Of The University Of California Procedes et compositions permettant de cibler des tissus specifiques
WO1993025698A1 (fr) 1992-06-10 1993-12-23 The United States Government As Represented By The Particules vecteurs resistantes a l'inactivation par le serum humain
WO1994003622A1 (fr) 1992-07-31 1994-02-17 Imperial College Of Science, Technology & Medicine Vecteurs retroviraux du type d, bases sur le virus du singe mason-pfizer
WO1994012649A2 (fr) 1992-12-03 1994-06-09 Genzyme Corporation Therapie genique de la fibrose kystique
WO1994023697A1 (fr) 1993-04-22 1994-10-27 Depotech Corporation Liposomes de cyclodextrine encapsulant des composes pharmacologiques et leurs procedes d'utilisation
WO1994028938A1 (fr) 1993-06-07 1994-12-22 The Regents Of The University Of Michigan Vecteurs d'adenovirus pour therapie genique
WO1995000655A1 (fr) 1993-06-24 1995-01-05 Mc Master University Vecteurs a base d'adenovirus destines a la therapie genique
WO1995007994A2 (fr) 1993-09-15 1995-03-23 Viagene, Inc. Vecteurs composes d'alphavirus recombinants
US5814482A (en) 1993-09-15 1998-09-29 Dubensky, Jr.; Thomas W. Eukaryotic layered vector initiation systems
WO1995011984A2 (fr) 1993-10-25 1995-05-04 Canji, Inc. Vecteur recombinant d'adenovirus et procedes d'utilisation
WO1995013796A1 (fr) 1993-11-16 1995-05-26 Depotech Corporation Vesicules a taux controle de liberation des principes actifs
WO1995030763A2 (fr) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Vecteurs retroviraux a taux de recombinaison reduit
WO1996017072A2 (fr) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Vecteurs d'alphavirus de recombinaison
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
WO1997042338A1 (fr) 1996-05-06 1997-11-13 Chiron Corporation Vecteurs retroviraux sans croisement
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods

Non-Patent Citations (93)

* Cited by examiner, † Cited by third party
Title
"ATLAS OF PROTEIN SEQUENCE AND STRUCTURE", 1979, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, pages: 353 - 358
"Biocomputing: Informatics and Genome Projects", 1993, ACADEMIC PRESS
"Clathrin triskelia show evidence of molecular flexibility", BIOPHYS J, vol. 95, 2008, pages 1945 - 55
"Computational Molecular Biology", 1988, OXFORD UNIVERSITY PRESS
"Computer Analysis of Sequence Data", 1994, HUMANA PRESS
"Guide to Huge Computers", 1994, ACADEMIC PRESS
"Remington, The Science and Practice of Pharmacy", 2000, MACK PUBLISHING
"Remington: The Science and Practice of Pharmacy", 1995
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO.
"Structure of clathrin coat with bound Hsc70 and auxilin: mechanism of Hsc70- facilitated disassembly", EMBO J, vol. 29, pages 655 - 65
ALBER ET AL., J. MOL. APPL. GENET., vol. 1, 1982, pages 419 - 434
ATSCHUL, S. F. ET AL., 1. MOLEC. BIOL., vol. 215, 1990, pages 403
BLIXT, M. K.; ROYLE, S. J.: "Clathrin heavy chain gene fusions expressed in human cancers: analysis of cellular functions", TRAFFIC, vol. 12, pages 754 - 61
BRODSKY, F. M.; CHEN, C. Y.; KNUEHL, C.; TOWLER, M. C.; WAKEHAM, D. E.: "Biological basket weaving: formation and function of clathrin-coated vesicles", ANNU REV CELL DEV BIOL, vol. 17, 2001, pages 517 - 68
BRODSKY, F. M.; HILL, B. L.; ACTON, S. L.; N6THKE, I.; WONG, D. H.; PONNAMBALAM, S.; PARHAM, P.: "Clathrin light chains: Arrays of protein motifs that regulate coated vesicle dynamics", TRENDS BIOL. SCI., vol. 16, 1991, pages 208 - 213, XP025864742, DOI: doi:10.1016/0968-0004(91)90087-C
BRUNGER, A. T.: "Version 1.2 of the Crystallography and NMR system", NAT PROTOC, vol. 2, 2007, pages 2728 - 33
BRUNGER, A. T.; ADAMS, P. D.; CLORE, G. M.; DELANO, W. L.; GROS, P.; GROSSE-KUNSTLEVE, R. W.; JIANG, J. S.; KUSZEWSKI, J.; NILGES,: "Crystallography & NMR system: A new software suite for macromolecular structure determination", ACTA CRYSTALLOGRAPHICA. SECTION D: BIOLOGICAL CRYSTALLOGRAPHY, vol. 54, 1998, pages 905 - 21
CARILLO ET AL., SIAM. APPLIED MATH, vol. 48, pages 1073
CARILLO ET AL., SIAM.I. APPLIED MATH, vol. 48, 1988, pages 1073
CHAKRABARTTY, A.; KORTEMME, T.; BALDWIN, R. L.: "Helix propensities of the amino acids measured in alanine-based peptides without helix-stabilizing side- chain interactions", PROTEIN SCI, vol. 3, 1994, pages 843 - 52
CHEN, C. Y.; BRODSKY, F. M.: "Huntingtin-interacting protein 1 (Hip1) and Hip1-related protein (Hip1 R) bind the conserved sequence of clathrin light chains and thereby influence clathrin assembly in vitro and actin distribution in vivo", J BIOL CHEM, vol. 280, 2005, pages 6109 - 17
CHIOU ET AL., GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER, 1994
CONNELLY, HUMAN GENE THERAPY, vol. 1, 1995, pages 185
CURIEL, HUM. GENE THER., vol. 3, 1992, pages 147
DAFFORN, T. R.; SMITH, C. J.: "Natively unfolded domains in endocytosis: hooks, lines and linkers", EMBO REP, vol. 5, 2004, pages 1046 - 52
DEN OTTER, W. K.; RENES, M. R.; BRIELS, W. J.: "Asymmetry as the key to clathrin cage assembly", BIOPHYS J, vol. 99, pages 1231 - 8
DEN OTTER, W. K.; RENES, M. R.; BRIELS, W. J.: "Self-assembly of three-legged patchy particles into polyhedral cages", J PHYS CONDENS MATTER, vol. 22, pages 104103, XP020173795
DEVEREUX, J . ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, no. 1, 1984, pages 387
DUNKER, A. K.; BROWN, C. J.; LAWSON, J. D.; LAKOUCHEVA, L. M.; OBRADOVIC, Z.: "Intrinsic disorder and protein function", BIOCHEMISTRY, vol. 41, 2002, pages 6573 - 82
ENARI, M.; OHMORI, K.; KITABAYASHI, I.; TAYA, Y.: "Requirement of clathrin heavy chain for p53-mediated transcription", GENES DEV, vol. 20, 2006, pages 1087 - 99
FINDEIS ET AL., TRENDS BIOTECHNOL., vol. 11, 1993, pages 202
FOTIN, A.; CHENG, Y.; SLIZ, P.; GRIGORIEFF, N.; HARRISON, S. C.; KIRCHHAUSEN, T.; WALZ, T.: "Molecular model for a complete clathrin lattice from electron cryomicroscopy", NATURE, vol. 432, 2004, pages 573 - 9
GOODMAN, O. B., JR.; KRUPNICK, J. G.; SANTINI, F.; GUREVICH, V. V.; PENN, R. B.; GAGNON, A. W.; KEEN, J. H.; BENOVIC, J. L.: "b-arrestin acts as a clathrin adaptor in endocytosis of the b2-adrenergic receptor", NATURE, vol. 383, 1996, pages 447 - 450
GRAGEROV, A.; ZENG, L.; ZHAO, X.; BURKHOLDER, W.; GOTTESMAN, M. E.: "Specificity of DnaK-peptide binding", J MOL BIOL, vol. 235, 1994, pages 848 - 54, XP024008630, DOI: doi:10.1006/jmbi.1994.1043
GRIBSKOV ET AL., NUCL. ACIDS RES., vol. 14, 1986, pages 6745
GRIBSKOV, M.; DEVEREUX, J: "Sequence Analysis Primer", 1991, M STOCKTON PRESS
HANNAN, L. A.; NEWMYER, S. L.; SCHMID, S. L.: "ATP- and cytosol- dependent release of adaptor proteins from clathrin-coated vesicles: A dual role for Hsc70", MOLECULAR BIOLOGY OF THE CELL, vol. 9, 1998, pages 2217 - 29
HARTL, F. U.; HAYER-HARTL, M.: "Molecular chaperones in the cytosol: from nascent chain to folded protein", SCIENCE, vol. 295, 2002, pages 1852 - 8, XP002506672, DOI: doi:10.1126/science.1068408
HEINJE, G.: "Sequence Analysis in Molecular Biology", 1987, ACADEMIC PRESS
HEYMANN, J. B.; IWASAKI, K.; YIM, Y. I.; CHENG, N.; BELNAP, D. M.; GREENE, L. E.; EISENBERG, E.; STEVEN, A. C.: "Visualization of the binding of Hsc70 ATPase to clathrin baskets: implications for an uncoating mechanism", J BIOL CHEM, vol. 280, 2005, pages 7156 - 61
HUANG, K. M.; GULLBERG, L.; NELSON, K. K.; STEFAN, C. J.; BLUMER, K.; LEMMON, S. K.: "Novel functions of clathrin light chains: clathrin heavy chain trimerization is defective in light chain-deficient yeast", J CELL SCI 110, 1997, pages 899 - 910
JIN, A. J.; NOSSAL, R.: "Rigidity of triskelion arms and clathrin nets", BIOPHYS J, vol. 78, 2000, pages 1183 - 94
JOEL A. YBE ET AL: "Contribution of Cysteines to Clathrin Trimerization Domain Stability and Mapping of Light Chain Binding", TRAFFIC, vol. 4, no. 12, 1 December 2003 (2003-12-01), pages 850 - 856, XP055043167, ISSN: 1398-9219, DOI: 10.1046/j.1600-0854.2003.0139.x *
JOEL A. YBE ET AL: "Light Chain C-Terminal Region Reinforces the Stability of Clathrin Heavy Chain Trimers", TRAFFIC, vol. 8, no. 8, 1 August 2007 (2007-08-01), pages 1101 - 1110, XP055043180, ISSN: 1398-9219, DOI: 10.1111/j.1600-0854.2007.00597.x *
JOLLY, CANCER GENE THERAPY, vol. 1, 1994, pages 51
JONES, T. A.; BERGDOLL, M.; KJELDGAARD, M.: "Crystallography and Modelling Methods in Molecular Design", 1990, SPRINGER-VERLAG, article "O: a macromolecule modelling environment", pages: 189 - 199
K OHMORI ET AL: "Monomeric but not trimeric clathrin heavy chain regulates p53-mediated transcription", ONCOGENE, vol. 27, no. 15, 3 April 2008 (2008-04-03), pages 2215 - 2227, XP055043523, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1210854 *
KAPLITT, NATURE GENETICS, vol. 6, 1994, pages 148
KETNER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 6186 - 6190 61
KIMURA, HUMAN GENE THERAPY, vol. 5, 1994, pages 845
KIRCHHAUSEN, T.: "Adaptors for clathrin-mediated traffic", ANNU. REV. OF CELL AND DEV. BIOL., vol. 15, 1999, pages 705 - 32
KIRCHHAUSEN, T.; HARRISON, S. C.; PARHAM, P.; BRODSKY, F. M.: "Location and distribution of the light chains in clathrin trimers", PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 2481 - 2485
KIRCHHAUSEN, T.; SCARMATO, P.; HARRISON, S. C.; MONROE, J. J.; CHOW, E. P.; MATTALIANO, R. J.; RAMACHANDRAN, K. L.; SMART, J. E.;: "Clathrin light chains LCa and LCb are similar, polymorphic, and share repeated heptad motifs", SCIENCE, vol. 236, 1987, pages 320 - 324
KOTOVA, S.; PRASAD, K.; SMITH, P. D.; LAFER, E. M.; NOSSAL, R.; JIN, A. J.: "AFM visualization of clathrin triskelia under fluid and in air", FEBS LETT, vol. 584, pages 44 - 8, XP026802256
KRUPNICK, J. G.; GOODMAN JR., O. B.; KEEN, J. H.; BENOVIC, J. L.: "Arrestin-clathrin interaction. Localization of the clathrin binding domain of nonvisual arrestins to the carboxyl terminus", J. BIOL. CHEM., vol. 272, 1997, pages 15011 - 15016, XP002278695, DOI: doi:10.1074/jbc.272.23.15011
LEGENDRE-GUILLEMIN, V.; METZLER, M.; LEMAIRE, J. F.; PHILIE, J.; GAN, L., HAYDEN, M. R.; MCPHERSON, P. S.: "Huntingtin interacting protein 1 (HIP1) regulates clathrin assembly through direct binding to the regulatory region of the clathrin light chain", J BIOL CHEM, vol. 280, 2005, pages 6101 - 8
LINDENBAUM ET AL., NUCLEIC ACIDS RES., vol. 32, no. 21, 2004, pages E172
LIU, S.-H.; WONG, M. L.; CRAIK, C. S.; BRODSKY, F. M.: "Regulation of clathrin assembly and trimerization defined using recombinant triskelion hubs", CELL, vol. 83, 1995, pages 257 - 267
MA, Y.; GREENER, T.; PACOLD, M. E.; KAUSHAL, S.; GREENE, L. E.; EISENBERG, E.: "Identification of domain required for catalytic activity of auxilin in supporting clathrin uncoating by Hsc70", J BIOL CHEM, vol. 277, 2002, pages 49267 - 74
MAHATO ET AL., PHARM. RES., vol. 14, 1997, pages 853 - 859
MCCOY, A. J.: "Solving structures of protein complexes by molecular replacement with Phaser", ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol. 63, 2007, pages 32 - 41
NEEDLEMAN ET AL., 1. MOL. BIOL., vol. 48, 1970, pages 443
NEWPHER, T. M.; IDRISSI, F. Z.; GELI, M. I.; LEMMON, S. K.: "Novel function of clathrin light chain in promoting endocytic vesicle formation", MOL BIOL CELL, vol. 17, 2006, pages 4343 - 52
NIU, Q.; YBE, J. A.: "Crystal structure at 2.8 A of Huntingtin-interacting protein 1 (HIP1) coiled-coil domain reveals a charged surface suitable for HIP1 protein interactor (HIPPI", J MOL BIOL, vol. 375, 2008, pages 1197 - 205, XP022411974, DOI: doi:10.1016/j.jmb.2007.11.036
OHATA H ET AL: "Identification of a Function-Specific Mutation of Clathrin Heavy Chain (CHC) Required for p53 Transactivation", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 394, no. 3, 4 December 2009 (2009-12-04), pages 460 - 471, XP026749020, ISSN: 0022-2836, [retrieved on 20090918], DOI: 10.1016/J.JMB.2009.09.029 *
OHATA, H.; OTA, N.; SHIROUZU, M.; YOKOYAMA, S.; YOKOTA, J.; TAYA, Y.; ENARI, M.: "Identification of a function-specific mutation of clathrin heavy chain (CHC) required for p53 transactivation", J MOL BIOL, vol. 394, 2009, pages 460 - 71, XP026749020, DOI: doi:10.1016/j.jmb.2009.09.029
OHMORI, K.; ENDO, Y.; YOSHIDA, Y.; OHATA, H.; TAYA, Y.; ENARI, M.: "Monomeric but not trimeric clathrin heavy chain regulates p53-mediated transcription", ONCOGENE, vol. 27, 2008, pages 2215 - 27, XP055043523, DOI: doi:10.1038/sj.onc.1210854
PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444
PHILIP, MOL. CELL BIOL., vol. 14, 1994, pages 2411
RAPOPORT, I.; BOLL, W.; YU, A.; BOCKING, T.; KIRCHHAUSEN, T.: "A motif in the clathrin heavy chain required for the Hsc70/auxilin uncoating reaction", MOL BIOL CELL, vol. 19, 2008, pages 405 - 13
ROBINSON, M. S.: "Adaptable adaptors for coated vesicles", TRENDS CELL BIOL, vol. 14, 2004, pages 167 - 74
ROTHMAN, J. E.; SCHMID, S. L.: "Enzymatic recycling of clathrin from coated vesicles", CELL, vol. 49, 1986, pages 5 - 9, XP023883986, DOI: doi:10.1016/0092-8674(86)90852-4
ROYLE, S. J.; BRIGHT, N. A.; LAGNADO, L.: "Clathrin is required for the function of the mitotic spindle", NATURE, vol. 434, 2005, pages 1152 - 7
ROYLE, S. J.; LAGNADO, L.: "Trimerisation is important for the function of clathrin at the mitotic spindle", J CELL SCI, vol. 119, 2006, pages 4071 - 8
RUSSELL, GENE, vol. 40, 1985, pages 125 - 130
SMITH; WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482
TER HAAR, E.; HARRISON, S. C.; KIRCHHAUSEN, T.: "Peptide-in-groove interactions link target proteins to the beta-propeller of clathrin", PROC NATL ACAD SCI U S A, vol. 97, 2000, pages 1096 - 100
TER HAAR, E.; MUSACCHIO, A.; HARRISON, S. C.; KIRCHHAUSEN, T.: "Atomic structure of clathrin: A b propeller terminal domain joins an a zigzag linker", CELL, vol. 95, 1998, pages 563 - 573, XP008116709, DOI: doi:10.1016/S0092-8674(00)81623-2
WANG, J.; WANG, Y.; O'HALLORAN, T. J.: "Clathrin light chain: importance of the conserved carboxy terminal domain to function in living cells", TRAFFIC, vol. 7, 2006, pages 824 - 32
WARD, J. J.; SODHI, J. S.; MCGUFFIN, L. J.; BUXTON, B. F.; JONES, D. T.: "Prediction and functional analysis of native disorder in proteins from the three kingdoms of life", J MOL BIOL, vol. 337, 2004, pages 635 - 45, XP004494590, DOI: doi:10.1016/j.jmb.2004.02.002
WILBUR, J. D.; HWANG, P. K.; YBE, J. A.; LANE, M.; SELLERS, B. D.; JACOBSON, M. P.; FLETTERICK, R. J.; BRODSKY, F. M.: "Conformation switching of clathrin light chain regulates clathrin lattice assembly", DEV CELL, vol. 18, pages 841 - 8
WOFFENDIN, PROC. NATL. ACAD. SCI., vol. 91, 1994, pages 1581
WU ET AL., J BIOL. CHEM., vol. 266, 1991, pages 338
WU ET AL., J. BIOL CHEM., vol. 263, 1988, pages 621
WU ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 542
WU5, J. BIOL. CHEM., vol. 264, 1989, pages 16985
YBE, J. A.; BRODSKY, F. M.; HOFMANN, K.; LIN, K.; LIU, S. H.; CHEN, L.; EARNEST, T. N.; FLETTERICK, R. J.; HWANG, P. K.: "Clathrin self-assembly is mediated by a tandemly repeated superhelix", NATURE, vol. 399, 1999, pages 371 - 5
YBE, J. A.; BRODSKY, F. M.; HOFMANN, K.; LIN, K.; LIU, S.-H.; CHEN, L.; EARNEST, T. N.; FLETTERICK, R. J.; HWANG, P. K.: "Clathrin self-assembly is mediated by a tandemly repeated superhelix", NATURE, vol. 399, 1999, pages 371 - 375
YBE, J. A.; PEREZ-MILLER, S.; NIU, Q.; COATES, D. A.; DRAZER, M. W.; CLEGG, M. E.: "Light chain C-terminal region reinforces the stability of clathrin heavy chain trimers", TRAFFIC, vol. 8, 2007, pages 1101 - 10, XP055043180, DOI: doi:10.1111/j.1600-0854.2007.00597.x
YBE, J. A.; RUPPEL, N.; MISHRA, S.; VANHAAFTEN, E.: "Contribution of cysteines to clathrin trimerization domain stability and mapping of light chain binding", TRAFFIC, vol. 4, 2003, pages 850 - 6, XP055043167, DOI: doi:10.1046/j.1600-0854.2003.0139.x
YOUNG, J. S.; GUTTMAN, J. A.; VAID, K. S.; SHAHINIAN, H.; VOGL, A. W.: "Cortactin (CTTN), N-WASP (WASL), and clathrin (CLTC) are present at podosome- like tubulobulbar complexes in the rat testis", BIOL REPROD, vol. 80, 2009, pages 153 - 61
YOUNG, M.; KIRSHENBAUM, K.; DILL, K. A.; HIGHSMITH, S.: "Predicting conformational switches in proteins", PROTEIN SCI, vol. 8, 1999, pages 1752 - 64
ZENKE ET AL., PROC. NATL. ACAD. SCL (USA, vol. 87, 1990, pages 3655

Similar Documents

Publication Publication Date Title
JP6766194B2 (ja) ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
US8343760B2 (en) p53 activator peptides
DK2661496T3 (en) FUSION PROTEIN AS ANTICANCING AGENT
JP2013515474A (ja) 組換え体ｈ因子ならびにそのバリアントおよびコンジュゲート
CA2590512A1 (fr) Proteine de fusion comprenant un domaine bh3 de proteine bh3 seulement
KR20170042366A (ko) 디스인테그린 변이체 및 이의 약학적 용도
AU2014228777A1 (en) BH4 stabilized peptides and uses thereof
CN101643511A (zh) 抑制端粒酶活性的融合蛋白、其制备及应用
US20210113685A1 (en) Polypeptide drug against hepatitis b virus protein
JP7531931B2 (ja) Ｖｇｌｌ１ペプチドを含む癌治療用組成物
JP2003210183A (ja) ヒトＩκＢ−β
WO2018109771A1 (fr) Protéines de fusion pour le traitement du cancer
CN110372780B (zh) 抗肿瘤多肽及其在抗肿瘤领域的应用
WO2013028527A1 (fr) Compositions et procédés pour traiter le cancer
US10457718B2 (en) Compounds for the treatment of cancer
JP2012533521A (ja) 治療剤
KR101478395B1 (ko) 세포사멸을 유도하는 방법 및 그 조성물
WO2011079431A1 (fr) Protéine de fusion ayant une activité inhibitrice de télomérase, son procédé de préparation et utilisation
CN102212126A (zh) 具有抑制内皮细胞生长活性的重组EDI-8t蛋白
JP2008505846A (ja) 悪性哺乳動物細胞および形質転換哺乳動物細胞に対して選択的に致死性を有するペプチド

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12753883

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12753883

Country of ref document: EP

Kind code of ref document: A1